Characterizing immune features of thymic epithelial tumors
Characterisation of the Immune Infiltrate and Molecular Features of Thymic Epithelial Tumors Tumors (TETs)
NA · Institut Curie · NCT05558644
This study is testing the immune features of thymic epithelial tumors in patients having surgery to see how these tumors behave and if new treatments can be developed.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 50 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Institut Curie (other) |
| Drugs / interventions | chemotherapy |
| Locations | 3 sites (Paris and 2 other locations) |
| Trial ID | NCT05558644 on ClinicalTrials.gov |
What this trial studies
The IMMUNO-TET trial aims to evaluate the immune environment and molecular characteristics of localized thymic epithelial tumors (TETs) in patients undergoing thymectomy or thymomectomy. This prospective study involves collecting blood samples and tumor specimens during surgery for comprehensive analysis, including flow cytometry and RNA sequencing. Additionally, the feasibility of developing patient-derived xenografts from TETs will be explored to test potential therapeutic agents. The study will follow patients through their surgical journey and post-operative care to assess immune responses and molecular profiles.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with a suspicion of localized thymic epithelial tumors who have not received prior treatment.
Not a fit: Patients with ongoing neoplasia or those who have received neoadjuvant chemotherapy may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and treatment options for patients with thymic epithelial tumors.
How similar studies have performed: While this approach is innovative, similar studies have shown promise in characterizing tumor microenvironments and developing xenograft models for cancer research.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patient with suspicion of localised thymic epithelial tumour. 2. Age ≥ 18 years. 3. Treatment-naïve patient for this disease. 4. Patient with an indication for thymectomy and thymomectomy in one of the partner centers. 5. Signed informed consent form of the patient. Exclusion Criteria: 1. Neoadjuvant chemotherapy. 2. No social security affiliation. 3. Person under legal protection. 4. Other neoplasia in progress or cured within the last 3 years (except for operated carcinoma in situ).
Where this trial is running
Paris and 2 other locations
- Institut Curie Paris — Paris, France (RECRUITING)
- Institut Mutualiste Montsouris — Paris, France (RECRUITING)
- Hôpital FOCH — Suresnes, France (RECRUITING)
Study contacts
- Study coordinator: Clémence BASSE, MD
- Email: clemence.basse@curie.fr
- Phone: 01 56 24 55 39
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Cancer, thymic epithelial tumors